Healthcare technology firm Casana has raised $30m in Series B funding led by Morningside to accelerate the development of its new home health monitoring technology.
Series A investors Outsiders Fund and General Catalyst participated in the funding round, along with private equity investment firm Matrix Partners.
This round has brought the total capital raised by Casana so far to $46m.
Casana intends to use the funds to develop and commercialise its patient-centred health monitoring product, The Heart Seat.
At present, the company is looking to obtain clearance for the product from the US Food and Drug Administration (FDA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
It aims to make the product available for patients this year.
The Heart Seat is an Internet of Things (IoT) health monitoring device that is built into a toilet seat.
It is designed to capture clinically relevant measurements, such as heart rate as well as blood oxygenation and pressure.
On its website, the company claims that the effortless device is developed to monitor patients’ consistent health data and support in-home healthcare management.
The patient-centred health monitoring technology is specially designed for people to manage and control high blood pressure, also called hypertension.
It is claimed to be the first commercial offering developed to monitor cuffless blood pressure.
Casana CEO Austin McChord said: “In a world overrun with push notifications, nudges and reminders, our product needs none of that.
“The Heart Seat is different from virtually every other vitals monitoring product, in that it takes no time out of your day and works best when you forget it’s even there.”
The company is also investing in studies to assess The Heart Seat’s potential value for health systems organisations.
